Bulletin n°92
Traitements
-
Combinaison de traitements localisés et systémiques (1)
-
File
Mené sur 747 patients atteints d'un cancer avancé du rectum, cet essai de phase III évalue l'ajout d'oxaliplatine à une chimioradiothérapie préopératoire
-
Bowel Resection Outcomes in Ovarian Cancer Cytoreductive Surgery by Surgeon Specialty
2023
-
-
Patients with head and neck cancer unfit for cisplatin - what next?
The Lancet Oncology, 2023
-
Radiotherapy with cetuximab or durvalumab for locoregionally advanced head and neck cancer in patients with a contraindication to cisplatin (NRG-HN004): an open-label, multicentre, parallel-group, randomised, phase 2/3 trial
The Lancet Oncology, 2023
-
Camrelizumab vs Placebo in Combination With Chemotherapy as Neoadjuvant Treatment in Patients With Early or Locally Advanced Triple-Negative Breast Cancer: The CamRelief Randomized Clinical Trial
JAMA, 2023
-
-
Are We Finally Ready for the Widespread Adoption of Stereotactic Radiation in Gynecologic Cancers?
JAMA Oncology, 2022
-
Quality-of-Life Outcomes and Toxic Effects Among Patients With Cancers of the Uterus Treated With Stereotactic Pelvic Adjuvant Radiation Therapy: The SPARTACUS Phase 1/2 Nonrandomized Controlled Trial
JAMA Oncology, 2022
-
Long-term efficacy and safety of ruxolitinib versus best available therapy in polycythaemia vera (RESPONSE): 5-year follow up of a phase 3 study
The Lancet Haematology, 2020
-
Polycythaemia vera, ruxolitinib, and hydroxyurea: where do we go now?
The Lancet Haematology, 2020
-
Obinutuzumab and ibrutinib induction therapy followed by a minimal residual disease-driven strategy in patients with chronic lymphocytic leukaemia (ICLL07 FILO): a single-arm, multicentre, phase 2 trial
The Lancet Haematology, 2019
-
5-year results for pembrolizumab treatment of advanced melanoma
The Lancet Oncology, 2019
-
Is chemoimmunotherapy maintenance of value in patients with chronic lymphocytic leukaemia and minimal residual disease?
The Lancet Haematology, 2019
-
Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study
The Lancet Oncology, 2019
-
Aurora kinase inhibitor nanoparticles target tumors with favorable therapeutic index in vivo
Science Translational Medicine, 2016
-
Are Accurins the cure for Aurora kinase inhibitors?
Science Translational Medicine, 2016
-
-
-
Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study
The Lancet Oncology, 2016
-
The net chance of a longer survival as a patient-oriented measure of treatment benefit in randomized clinical trials
JAMA Oncology, 2016
-
Quality of life in patients with advanced renal cell carcinoma given nivolumab versus everolimus in CheckMate 025: a randomised, open-label, phase 3 trial
The Lancet Oncology, 2016
-
Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial
The Lancet Haematology, 2016
-
Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial
The Lancet, 2016
-
-
-
Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy
Nature, 2016
-
Neratinib plus paclitaxel vs trastuzumab plus paclitaxel in previously untreated metastatic ERBB2-positive breast cancer: The NEfERT-T randomized clinical trial
JAMA Oncology, 2016
-
Defining optimal initial therapy for primary CNS lymphoma
The Lancet Haematology, 2016
-
-
-
Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial
Journal of Clinical Oncology, 2015
-
Trabectedin and the L-Sarcomas: A Decade-Long Odyssey
Journal of Clinical Oncology, 2015
-
-
Gefitinib and Erlotinib in Metastatic Non-Small Cell Lung Cancer: A Meta-Analysis of Toxicity and Efficacy of Randomized Clinical Trials
The Oncologist, 2015
-
Randomized Phase III Trial Comparing Weekly Docetaxel Plus Cisplatin Versus Docetaxel Monotherapy Every 3 Weeks in Elderly Patients With Advanced Non–Small-Cell Lung Cancer: The Intergroup Trial JCOG0803/WJOG4307L
Journal of Clinical Oncology, 2015
-
Minimize Toxicity or Preserve Efficacy? A Delicate Trade-Off in the Management of Older Patients With Lung Cancer
Journal of Clinical Oncology, 2015
-
Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial
The Lancet Oncology, 2015
-
Cediranib combined with carboplatin and paclitaxel in patients with metastatic or recurrent cervical cancer (CIRCCa): a randomised, double-blind, placebo-controlled phase 2 trial
The Lancet Oncology, 2015
-
Clinical implications for cediranib in advanced cervical cancer
The Lancet Oncology, 2015
-
Anti-EGFR monoclonal antibodies in lung cancer treatment
The Lancet Oncology, 2015
-
Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial
The Lancet Oncology, 2015
-
Intravenous pegylated asparaginase versus intramuscular native Escherichia coli l-asparaginase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05-001): a randomised, open-label phase 3 trial
The Lancet Oncology, 2015
-
-
Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial
The Lancet Oncology, 2015
-
Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial
The Lancet Oncology, 2015
-
Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial
The Lancet Oncology, 2015
-
-
CSF1R inhibition with emactuzumab in locally advanced diffuse-type tenosynovial giant cell tumours of the soft tissue: a dose-escalation and dose-expansion phase 1 study
The Lancet Oncology, 2015
-
The growing problem of benign connective tissue tumours
The Lancet Oncology, 2015
-
-
-
-
Traitements localisés : applications cliniques (1)
-
A partir de données issues des registres américains du cancer et portant sur 3 996 patients âgés, cette étude évalue l'impact de complications chirurgicales consécutives à la résection d'un cancer du poumon non à petites cellules de stade I sur la survie à long terme
The Long-term Impact of Surgical Complications After Resection of Stage I Nonsmall Cell Lung Cancer: A Population-based Survival Analysis
2011
-
-
Traitements systémiques : applications cliniques (2)
-
Cet article passe en revue les travaux récents sur le traitement néo-adjuvant d'un cancer du sein de stade précoce
-
Cet article passe en revue la littérature sur l'efficacité et la sécurité d'une chimiothérapie palliative pour des patientes atteintes d'un cancer du sein de stade avancé et ayant reçu préalablement des traitements avec anthracyclines et taxanes
Efficacy and safety of palliative chemotherapy for patients with advanced breast cancer pretreated with anthracyclines and taxanes: a systematic review
The Lancet Oncology, 2011
-
-
Traitements systémiques : découverte et développement (8)
-
Menée in vitro et à l'aide de xénogreffes, cette étude évalue la capacité d'un composé appelé SKLB1002 à inhiber l'angiogenèse et la croissance tumorale
SKLB1002, a Novel Potent Inhibitor of VEGF Receptor 2 Signaling, Inhibits Angiogenesis and Tumor Growth In Vivo
Clinical Cancer Research, 2011
-
Mené sur 113 patients ayant été traités pour un sarcome avancé des tissus mous, cet essai de phase II évalue l'ajout de gemcitabine à la dacarbazine
Randomized Phase II Study Comparing Gemcitabine Plus Dacarbazine Versus Dacarbazine Alone in Patients With Previously Treated Soft Tissue Sarcoma: A Spanish Group for Research on Sarcomas Study
Journal of Clinical Oncology, 2011
-
Menée in vitro et in vivo, cette étude montre que le sorafenib augmente l'activité cytotoxique du pemetrexed par un mécanisme d'autophagie
Sorafenib enhances pemetrexed cytotoxicity through an autophagy -dependent mechanism in cancer cells
Cancer Research, 2011
-
Menée in vitro et à l'aide de xénogreffes, cette étude montre que le dacetuzumab augmente l'efficacité du rituximab dans le lymphome non hodgkinien
Distinct apoptotic signaling characteristics of the anti-CD40 monoclonal antibody dacetuzumab and rituximab produce enhanced antitumor activity in NHL
Clinical Cancer Research, 2011
-
Cet article passe en revue les perspectives offertes par les thérapies photodynamiques des cancers
Photodynamic therapy of cancer: An update
CA: A Cancer Journal for Clinicians, 2011
-
Cet article passe en revue les perspectives offertes par le ciblage de la voie de signalisation Hedgehog dans le traitement des cancers
-
Menée sur différentes lignées de cellules de mélanome, cette étude évalue l'effet d'un traitement combinant vemurafenib et metformine
Combination therapy with vemurafenib (PLX4032/RG7204) and metformin in melanoma cell lines with distinct driver mutations
2011
-
Cet article passe en revue les développements actuels en immunothérapie pour le traitement du cancer de la prostate
Immunotherapy for the treatment of prostate cancer
Nature Reviews Clinical Oncology, 2011
-